ANRO Insider Trading Activity and SEC Form 4 Filings
ANRO insider trading summary
Over the past 12 months, insiders at Alto Neuroscience, Inc. (ANRO) reported 3 sales worth $3.6M by 1 insider and no open-market purchases on SEC Form 4. Net insider selling was $3.6M.
Latest ANRO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Nicholas Conrad Smith | President and CFO | Sell | $597K (23,170 @ $25.78) |
| Sep 30, 2026 | Nicholas Conrad Smith | President and CFO | Sell | $24K (886 @ $26.87) |
| Sep 29, 2026 | Nicholas Conrad Smith | President and CFO | Sell | $2.9M (110,830 @ $26.58) |
| Jul 10, 2024 | Adam Savitz | Chief Medical Officer | Buy | $39K (2,931 @ $13.22) |
| Jul 9, 2024 | Adam Savitz | Chief Medical Officer | Buy | $18K (1,388 @ $13.15) |
| Jul 9, 2024 | Adam Savitz | Chief Medical Officer | Buy | $134K (10,681 @ $12.53) |
| Mar 28, 2024 | Nicholas Conrad Smith | Chief Financial Officer | Buy | $75K (4,550 @ $16.56) |
| Mar 28, 2024 | Nicholas Conrad Smith | Chief Financial Officer | Buy | $25K (1,600 @ $15.80) |
| Feb 6, 2024 | Alpha Wave Global, LP | 10% Owner | Buy | $9.6M (600,000 @ $16.00) |
| Feb 6, 2024 | Lunate Holding RSC Ltd | 10% Owner | Buy | $9.6M (600,000 @ $16.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.